|
|
|
|
| LEADER |
01591nam a2200337 u 4500 |
| 001 |
EB001999824 |
| 003 |
EBX01000000000000001162725 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 100 |
1 |
|
|a Pohar, Ron
|
| 245 |
0 |
0 |
|a Combination use of ivabradine with sacubitril/valsartan
|h Elektronische Ressource
|b a review of clinical effectiveness and guidelines
|c Ron Pohar, Danielle MacDougall
|
| 250 |
|
|
|a Version: 1.0
|
| 260 |
|
|
|a Ottawa
|b Canadian Agency for Drugs and Technologies in Health
|c 2020, February 13, 2020
|
| 300 |
|
|
|a 1 PDF file (10 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Angiotensin Receptor Antagonists / therapeutic use
|
| 653 |
|
|
|a Drug Combinations
|
| 653 |
|
|
|a Ivabradine / therapeutic use
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Guidelines as Topic
|
| 653 |
|
|
|a Heart Failure / drug therapy
|
| 700 |
1 |
|
|a MacDougall, Danielle
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u http://www.ncbi.nlm.nih.gov/books/NBK562925
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 700
|
| 520 |
|
|
|a The objective of this report is to provide a summary of the evidence of clinical effectiveness and clinical practice guidelines regarding the combination of ivabradine and sacubitril/valsartan for the treatment of heart failure
|